Navigation Links
[video] Ronald Andrews, CEO of Clarient, Inc. Discusses Agreement With University of Pennsylvania School of Medicine on WallSt.net's 3-Minute Press Show
Date:10/2/2008

ALISO VIEJO, Calif., Oct. 2 /PRNewswire-FirstCall/ -- Clarient, Inc. (Nasdaq: CLRT), a premier anatomic pathology and molecular testing services resource for pathologists, oncologists and the pharmaceutical industry, today announced that the company's CEO, Ronald Andrews, is featured in an exclusive interview on WallSt.net's 3-Minute Press Show.

The interview gives viewers an overview of the company, and the significance of the company's latest press release.

To view the clip in its entirety, visit:

http://www.tv.wallst.net/r/3-minute-press/Ron-Andrews-CLRT-ND/278/1108

Ask Ronald Andrews a question, post a comment on his personal page, and join his financial social network today at:

http://my.wallst.net/Ron-Andrews-CLRT-ND

About Clarient, Inc.:

Clarient combines innovative technologies with world-class expertise to assess and characterize cancer. Clarient's mission is to provide the services, resources and critical information to improve the quality and reduce the cost of patient care, and accelerate the drug development process. The Company's principal customers include pathologists, oncologists, hospitals and biopharmaceutical companies. The rise of individualized medicine as the new direction in oncology has created the need for a centralized resource providing leading diagnostic technologies such as flow cytometry and molecular testing. Clarient is that resource, having created a state-of-the-art commercial cancer laboratory providing the most advanced oncology testing and drug development services available both onsite and over the web. Clarient is a Safeguard Scientifics partner company. http://www.clarientinc.com.

About WallStreet Direct, Inc.

WallStreet Direct, Inc. operates WallSt.net (http://www.wallst.net), a leading source of up-to-the-minute business news, comprehensive financial tools and original multimedia content for the investment community. In addition to WallSt.net, WallStreet Direct owns and operates WallStRadio (http://radio.wallst.net), an online hub for business podcasts from well-known business news personalities and publishers, and WallStTV (http://tv.wallst.net), a hub for business and finance video content. We have received one thousand seven hundred dollars from Clarient, Inc. in 2007 for media and advertising services, and an additional two hundred eighty dollars from Clarient, Inc. for the dissemination of this press release. To read our full disclaimer, and for a complete list of our advertisers, and advertising relationships, visit http://www.wallst.net/disclaimer/disclaimer.php.

Contact: WallStreet Direct, Inc.

800-4-WALLST

(Logo: http://www.newscom.com/cgi-bin/prnh/20050927/LATU121LOGO )


'/>"/>
SOURCE Clarient, Inc.; WallStreet Direct, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. [video] David Brown, President and CEO of LifeVantage Corporation, Discusses Record Page Views on WallSt.nets 3-Minute Press Show
2. [video] Jacques Tizabi, CEO of Universal Detection Technology Discusses Latest Purchase Order on WallSt.nets 3-Minute Press Show
3. [video] Edward Spink, CEO of TurboSonic Technologies, Inc. Discusses Contract With Biofuel Producer in Exclusive Interview on WallSt.nets 3-Minute Press Show
4. MiMedx Group, Inc. Adds Ronald G. Wallace to Board of Directors
5. Neurobiological Technologies, Inc. Reports Retirement of Ronald E. Cape, Ph.D., from Board
6. Kiwa Bio-Tech Products Group Discusses Cooperative Research With the University of Waterloo, Canada
7. Kiwa Bio-Tech Products Group Discusses Cooperative Efforts With Canadian Agricultural Ministry and Canadian Company
8. Insmed President Interviewed for Follow-On Biologics Podcast: Insmed Inc. President Steve Glover Discusses Safe and Effective Biologic Therapies and Reduced Costs with The American Magazine
9. Syngenta and Metabolon Inc. in Collaborative Research Agreement for Biochemical Profiling Technology
10. Micromet Announces Definitive Agreement for $40 Million Private Equity Placement
11. RainDance Technologies Signs a Collaboration Agreement with sanofi-aventis and Louis Pasteur University to Launch dScreen Consortium within ALSACE BIOVALLEY cluster
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... , March 22, 2017 The ... states a research report by Transparency Market Research (TMR). ... Amgen Inc., and AbbVie Inc., accounted for a share ... prominent players in this market are focusing aggressively on ... portfolio, which is likely to lead to market consolidation ...
(Date:3/22/2017)... ... ... Premier executive recruitment firm, Slone Partners, is proud to have been named ... , Hunt Scanlon Media is one of the most respected life science publications ... human capital sector. , “It is a great honor for Slone Partners to be ...
(Date:3/22/2017)... ... March 21, 2017 , ... The Conference Forum has announced the launch of ... on May 10-11, 2017, at the Colonnade Hotel in Boston, MA. The CMO Summit ... peer-to-peer learning, benchmarking and support. , “The Chief Medical Officer faces a unique set ...
(Date:3/22/2017)... HACKENSACK, N.J. and PETACH TIKVAH, ... Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult ... Chaim Lebovits , Chief Executive Officer, will provide ... at Sachs Associates 2 nd Annual Neuroscience Biopartnering ... at the New York Academy of Sciences. ...
Breaking Biology Technology:
(Date:3/2/2017)... Australia , March 2, 2017 Australian ... Ltd (ASX: CYP), has signed an agreement with ... from the Monash Biomedicine Discovery Institute and Department of ... to conduct a further preclinical study to support the ... treatment of asthma.  Asthma is a ...
(Date:2/27/2017)...   Strategic Cyber Ventures , the industry,s first ... $3.5 million investment in  Polarity , the first commercial ... DC based and is led by cybersecurity veterans ... Ron Gula , also a longtime cybersecurity veteran and ... series A round of funding. This new funding will ...
(Date:2/21/2017)... Der weltweite Biobanking-Sektor wird bis ... Gespräch mit mehr als 50 Vertretern aus verschiedenen Branchen wurde ... um diese Prognose zu realisieren. ... Zu den Schwierigkeiten ... Mittel für die Biobank, die Implementierung Zeit sparender Technologien, ...
Breaking Biology News(10 mins):